Aprepitant intravenous - Heron Therapeutics

Drug Profile

Aprepitant intravenous - Heron Therapeutics

Alternative Names: Cinvanti; HTX-019

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heron Therapeutics
  • Class Antidepressants; Antiemetics; Fluorobenzenes; Morpholines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 09 Nov 2017 Registered for Chemotherapy induced nausea and vomiting (Prevention, Combination therapy) in USA (IV)
  • 09 Nov 2017 Adverse event data from two bioequivalence clinical trials in Chemotherapy induced nausea and vomiting released by Heron Therapeutics
  • 06 Nov 2017 Heron Therapeutics announces intention to launch aprepitant intravenous in Chemotherapy induced nausea and vomiting (Prevention) in USA in January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top